Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer

Area of Science:

• Microbiology
• Pharmacology
• Oncology

Background:

• Endocrine therapy is crucial for prostate cancer treatment.
• Flutamide, an antiandrogen, faces challenges due to therapeutic resistance.
• The role of gut microbiota in drug metabolism and resistance is increasingly recognized.

Purpose of the Study:

• To investigate the contribution of gut microbiota to Flutamide resistance in prostate cancer.
• To identify specific microbial species and metabolic pathways involved in Flutamide degradation.
• To explore the potential for modulating gut microbiota to improve antiandrogen therapy efficacy.

Main Methods:

• Metabolomic analysis of Flutamide in the presence of gut bacteria.
• Identification of key bacterial genes (e.g., E. coli nfsA, nfsB) and enzymes involved in Flutamide metabolism.
• In vivo studies using antibiotic-treated mice and xenograft models.
• Analysis of clinical samples to assess interpatient variability in Flutamide metabolism.

Main Results:

• Gut bacteria, including Escherichia coli, metabolize Flutamide into inactive compounds FLU-6 and FLU-9.
• Specific genes (nfsA, nfsB) and acetyltransferases in E. coli are essential for these metabolic transformations.
• Antibiotic treatment reduced Flutamide metabolites in mice, and E. coli administration decreased Flutamide efficacy in vivo.
• Host metabolism further converted FLU-6 to FLU-5, with none of these metabolites exhibiting anticancer activity.
• Clinical samples showed significant interpatient variability in metabolic capabilities.

Conclusions:

• Gut microbiota plays a significant role in Flutamide resistance by metabolizing the drug into inactive forms.
• Understanding individual gut microbiome composition can inform personalized prostate cancer treatment strategies.
• Targeting or modulating gut microbiota may offer a novel approach to enhance the efficacy of antiandrogen therapies like Flutamide.